DAB2IP and ovarian carcinoma: In another study, treatment with the EZH2 inhibitor GSK-126 in combination with the RAC1 inhibitor NSC23766, eliminated ovarian cancer stem cells in vitro and increased platinum sensitivity in vivo, probably by synergically reinforcing the inhibitory effect on WNT signaling consequent to DAB2IP restoration [9] (Table 2).